October 21, 2009
FDA Acceptance of US Submission of Cellegesic™ (nitroglycerin) 0.4% Ointment
October 6, 2009
ProStrakan Announces Abstral NDA Filing
May 12, 2009
ProStrakan Announces US Submission of Fortigel (testosterone) 2% Gel
May 12, 2009
ProStrakan Announces US Co-Promotion Agreement for Oncology Support Product, Gelclair®
November 4, 2008
Now available SANCUSO®, the first and only patch for CINV
September 15, 2008
FDA Approves SANCUSO®, the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
July 31, 2008
ProStrakan and Orexo Extend Licensing Agreement for Rapinyl/Abstral to Include North America
February 19, 2008
New Survey Shows Oncology Nurses Urge “Zero Tolerance” Policy to Prevent Nausea and Vomiting in Patients
January 28, 2008
Board Change
January 14, 2008
Director/PDMR Shareholding
January 8, 2008
ProStrakan Reports Further Strong Progress in Preclose Update
January 7, 2008
Grant of Awards and Options